Overview
- Viking reported a third-quarter loss of $0.81 per share, missing the $0.72 loss expected by analysts.
- Research and development spending rose to $90 million from $22.8 million year over year, contributing to a larger net loss.
- Shares climbed roughly 11% to $34.90 intraday as investors reacted to clinical updates, according to Benzinga Pro.
- Phase 3 for the company’s injectable weight-loss candidate is proceeding on schedule, and the oral version produced up to 26.6 pounds of average weight loss over 13 weeks in Phase 2.
- Viking said it plans to file an IND for its amylin agonist in the first quarter and to share additional data at industry conferences in November.